fda tirzepatide approval Tirzepatide: First | Drugs Lilly Rises on FDA Approval

Great experience with multiple options of therapy

But the more important question is: which option fits your life in a way you can maintain

Clinical trials show that 5-10% of patients report headaches as a side effect during the first two weeks of semaglutide treatment

In February 2025, Sanofi received FDA approval for MERILOG, the first rapid-acting insulin aspart biosimilar, to improve glycemic control in adults and pediatric patients with diabetes

We included studies using any drug intervention that is currently or has previously been licensed for weight loss, or where there is reason to believe that the drug studied shares a class effect with a currently or previously licensed drug